Reported Earnings • May 01
Third quarter 2026 earnings: EPS misses analyst expectations Third quarter 2026 results: EPS: PK₨0.84 (up from PK₨0.27 in 3Q 2025). Revenue: PK₨9.73b (up 39% from 3Q 2025). Net income: PK₨491.5m (up 214% from 3Q 2025). Profit margin: 5.0% (up from 2.2% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 55%. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Announcement • Apr 22
The Searle Company Limited to Report Q3, 2026 Results on Apr 29, 2026 The Searle Company Limited announced that they will report Q3, 2026 results on Apr 29, 2026 Reported Earnings • Feb 28
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: PK₨9.96b (up 35% from 2Q 2025). Net income: PK₨891.7m (up 88% from 2Q 2025). Profit margin: 9.0% (up from 6.4% in 2Q 2025). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to PK₨92.24, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 105% over the past three years. Announcement • Feb 19
The Searle Company Limited to Report First Half, 2026 Results on Feb 26, 2026 The Searle Company Limited announced that they will report first half, 2026 results on Feb 26, 2026 Announcement • Jan 15
the Searle Company Limited Announces Board Changes The Searle Company Limited announces appointment of Arshad Anis as the chairman of the boar of the directors of the company with effect from January 14, 2026. board also appointed Zubair Razzak Palwala as the member of audit committee in pace of Mr. Adnan Asdar Ali. Announcement • Jan 02
The Searle Company Limited Announces Board Changes The Searle Company Limited announced that Mr. Adnan Asdar Ali has tendered his resignation as Director of the Company, who was also serving as Chairman of the Board, with effect from December 31, 2025. Mr. Arshad Anis has been appointed as the Director of the Company in place of Mr. Adnan Asdar Ali, with effect from January 1, 2026. New Risk • Nov 06
New major risk - Revenue and earnings growth Earnings have declined by 32% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 07
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: PK₨1.53 (down from PK₨2.12 in FY 2024). Revenue: PK₨28.6b (down 2.7% from FY 2024). Net income: PK₨781.1m (down 23% from FY 2024). Profit margin: 2.7% (down from 3.4% in FY 2024). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Announcement • Oct 07
The Searle Company Limited, Annual General Meeting, Oct 28, 2025 The Searle Company Limited, Annual General Meeting, Oct 28, 2025. Location: indus suite, avari towers,fatima jinnah road, karachi-75530 Pakistan Announcement • Sep 05
Mabwell Secures Pakistan's First Denosumab Injection Approval Mabwell and Pakistan's The Searle Company Limited jointly announced that two denosumab products, 9MW0311 and 9MW0321, have received marketing authorization from Drug Regulatory Authority of Pakistan (DRAP). This marks both Pakistan's first regulatory approval for a denosumab biosimilar and Mabwell's first overseas marketing authorization for its products. As a key Belt and Road Initiative partner with a population of 240 million, Pakistan presents substantial pharmaceutical market potential, aligning with Mabwell's strategic expansion into high-growth emerging markets. Earlier, Mabwell entered into a licensing agreement with Searle to facilitate local fill-finish and commercialization of Denosumab in Pakistan. About 9MW0311: 9MW0311 is a recombinant fully humanized anti-RANKL monoclonal antibody injection (60mg), developed as a Prolia® biosimilar. On March 28, 2023, the marketing application for 9MW0311 was approved by the National Medical Products Administration (NMPA) for the treatment of postmenopausal women with osteoporosis at high risk of fracture in China. Additional supplemental applications are planned to expand indications, including: osteoporosis in men at high risk of fracture, and glucocorticoid-induced osteoporosis in patients at high fracture risk. According to Frost & Sullivan data, the global market size for RANKL monoclonal antibody therapies in osteoporosis treatment has reached $1.317 billion in 2024. About 9MW0321: 9MW0321 is a recombinant fully humanized anti-RANKL monoclonal antibody injection (120mg) developed as a XGEVA® biosimilar. The NMPA of China granted marketing approval for 9MW0321 on March 29, 2024, establishing it as China's first approved XGEVA® biosimilar. It is indicated for the treatment of adults and skeletally mature adolescents (defined as at least 1 mature long bone and weighing = 45 kg) with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Mabwell is currently advancing supplementary applications to extend 9MW0321's indications to include malignancies associated with bone metastasis. BeOne Medicines and Amgen reported commercial performance data showing XGEVA® achieved annual sales of RMB 1.598 billion in China and USD 2.225 billion globally during 2024, with first half 2025 sales reaching RMB 1.090 billion in China and USD 1.098 billion worldwide. Future growth is anticipated to be predominantly driven by expansion in China and emerging markets. New Risk • Aug 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to PK₨111, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 22x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 38% over the past three years. Announcement • Jul 03
the Searle Company Limited Announces Director Changes The Searle Company Limited has announced the appointment of Mr. Tahir Ahmed as its new director, succeeding Ms. Faiza Naeem. This change is set to take place on July 1, 2025. According to information available from the Pakistan Stock Exchange (PSX), the appointment of Mr. Ahmed is part of the company's strategic realignment efforts. Market analysts are closely monitoring this development, given its potential impact on the company's governance and future outlook. Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to PK₨101, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 29% over the past three years. Valuation Update With 7 Day Price Move • May 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to PK₨66.65, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 16% over the past three years. Reported Earnings • Mar 04
Second quarter 2025 earnings released Second quarter 2025 results: EPS: PK₨0.92. Revenue: PK₨7.37b (down 20% from 2Q 2024). Net income: PK₨474.7m (up PK₨474.7m from 2Q 2024). Profit margin: 6.4% (up from 0% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to PK₨97.94, the stock trades at a trailing P/E ratio of 50.9x. Average trailing P/E is 23x in the Pharmaceuticals industry in Pakistan. Total loss to shareholders of 6.0% over the past three years. New Risk • Dec 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (31% increase in shares outstanding). Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to PK₨92.75, the stock trades at a trailing P/E ratio of 48.2x. Average trailing P/E is 21x in the Pharmaceuticals industry in Pakistan. Total loss to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to PK₨86.00, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 20x in the Pharmaceuticals industry in Pakistan. Total loss to shareholders of 31% over the past three years. Reported Earnings • Oct 10
Full year 2024 earnings released: EPS: PK₨3.47 (vs PK₨0.80 in FY 2023) Full year 2024 results: EPS: PK₨3.47 (up from PK₨0.80 in FY 2023). Revenue: PK₨29.4b (down 13% from FY 2023). Net income: PK₨1.57b (up 402% from FY 2023). Profit margin: 5.4% (up from 0.9% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance. Announcement • Oct 09
The Searle Company Limited, Annual General Meeting, Oct 28, 2024 The Searle Company Limited, Annual General Meeting, Oct 28, 2024. Location: karachi Pakistan New Risk • Jul 04
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Earnings have declined by 20% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (31% increase in shares outstanding). New Risk • Jun 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Shareholders have been diluted in the past year (31% increase in shares outstanding). Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to PK₨60.40, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 54% over the past three years. New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.3x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.1% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (PK₨23.7b market cap, or US$85.2m). Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to PK₨61.86, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 55% over the past three years. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to PK₨48.19, the stock trades at a trailing P/E ratio of 59.9x. Average trailing P/E is 20x in the Pharmaceuticals industry in Pakistan. Total loss to shareholders of 64% over the past three years. Announcement • Nov 04
The Searle Company Limited Announces Board Changes The Searle Company Limited has elected seven new directors at its Annual General Meeting held on October 27, 2023, at Khursheed Mehal, Avari Towers, Karachi. The meeting, which commenced at 4:30 p.m., concluded with the election of the following individuals to the board for a three-year term commencing from the date of election: Mr. Adnan Asdar Ali, Mr. S. Nadeem Ahmed, Mr. Zubair Razzak Palwala, Mr. Munis Abdullah, Ms. Faiza Abdulla, Ms. Shaista Khaliq Rehman, Mr. Muhammad Zubair Haider Shaikh. New Risk • Aug 23
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (3.4% net profit margin). Market cap is less than US$100m (PK₨15.6b market cap, or US$52.1m). Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to PK₨42.06, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 71% over the past three years. Buying Opportunity • Aug 09
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be PK₨55.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 187% in the next 2 years. Reported Earnings • Mar 08
Second quarter 2023 earnings released: EPS: PK₨0.93 (vs PK₨1.36 in 2Q 2022) Second quarter 2023 results: EPS: PK₨0.93 (down from PK₨1.36 in 2Q 2022). Revenue: PK₨8.64b (up 26% from 2Q 2022). Net income: PK₨364.6m (down 31% from 2Q 2022). Profit margin: 4.2% (down from 7.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Atta Rahman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 08
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: PK₨7.54 (down from PK₨12.15 in FY 2021). Revenue: PK₨29.9b (up 14% from FY 2021). Net income: PK₨2.35b (down 36% from FY 2021). Profit margin: 7.9% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 43%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jun 24
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from PK₨31.7b to PK₨30.0b. EPS estimate rose from PK₨14.75 to PK₨18.40. Net income forecast to shrink 37% next year vs 20% growth forecast for Pharmaceuticals industry in Pakistan . Consensus price target down from PK₨275 to PK₨225. Share price was steady at PK₨105 over the past week. Reported Earnings • May 08
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: EPS: PK₨1.97 (down from PK₨2.13 in 3Q 2021). Revenue: PK₨7.63b (flat on 3Q 2021). Net income: PK₨614.8m (down 7.4% from 3Q 2021). Profit margin: 8.1% (down from 8.7% in 3Q 2021). Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 22%. Over the next year, revenue is forecast to grow 23%, compared to a 22% growth forecast for the industry in Pakistan. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target increased to PK₨275 Up from PK₨208, the current price target is an average from 2 analysts. New target price is 142% above last closing price of PK₨114. Stock is down 38% over the past year. The company is forecast to post earnings per share of PK₨14.75 for next year compared to PK₨12.15 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Atta Rahman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 03
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: EPS: PK₨1.70 (down from PK₨3.10 in 2Q 2021). Revenue: PK₨6.89b (up 1.1% from 2Q 2021). Net income: PK₨529.9m (down 38% from 2Q 2021). Profit margin: 7.7% (down from 13% in 2Q 2021). Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 22%. Over the next year, revenue is forecast to grow 19%, compared to a 19% growth forecast for the industry in Pakistan. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to PK₨138, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 20x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 29% over the past three years. Price Target Changed • Nov 09
Price target increased to PK₨230 Up from PK₨209, the current price target is provided by 1 analyst. New target price is 32% above last closing price of PK₨175. Stock is down 6.9% over the past year. The company is forecast to post earnings per share of PK₨11.10 for next year compared to PK₨12.15 last year. Upcoming Dividend • Oct 22
Upcoming dividend of PK₨2.00 per share Eligible shareholders must have bought the stock before 29 October 2021. Payment date: 18 November 2021. Trailing yield: 0.9%. Lower than top quartile of Pakistani dividend payers (11%). Lower than average of industry peers (3.3%). Upcoming Dividend • Oct 13
Upcoming dividend of PK₨2.00 per share Eligible shareholders must have bought the stock before 20 October 2021. Payment date: 18 November 2021. Trailing yield: 1.0%. Lower than top quartile of Pakistani dividend payers (10%). Lower than average of industry peers (3.4%). Reported Earnings • Oct 06
Full year 2021 earnings released: EPS PK₨15.80 (vs PK₨11.77 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: PK₨26.2b (up 28% from FY 2020). Net income: PK₨3.68b (up 47% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Major Estimate Revision • May 27
Consensus revenue estimates increase to PK₨27.5b The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from PK₨23.8b to PK₨27.5b. EPS estimate increased from PK₨12.45 to PK₨13.00 per share. Net income forecast to grow 10% next year vs 18% growth forecast for Pharmaceuticals industry in Pakistan. Consensus price target up from PK₨257 to PK₨272. Share price was steady at PK₨239 over the past week. Reported Earnings • Apr 29
Third quarter 2021 earnings released: EPS PK₨2.77 (vs PK₨2.87 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: PK₨7.62b (up 46% from 3Q 2020). Net income: PK₨663.8m (up 8.9% from 3Q 2020). Profit margin: 8.7% (down from 12% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Feb 28
Revenue misses expectations Revenue missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 18%, compared to a 731% growth forecast for the Pharmaceuticals industry in Pakistan. Reported Earnings • Feb 27
Second quarter 2021 earnings released: EPS PK₨4.03 (vs PK₨2.67 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: PK₨6.82b (up 38% from 2Q 2020). Net income: PK₨855.2m (up 51% from 2Q 2020). Profit margin: 13% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year. Price Target Changed • Feb 09
Price target raised to PK₨276 Up from PK₨252, the current price target is an average from 3 analysts. The new target price is close to the current share price of PK₨270. As of last close, the stock is up 60% over the past year. Is New 90 Day High Low • Feb 02
New 90-day high: PK₨272 The company is up 12% from its price of PK₨243 on 04 November 2020. The Pakistani market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is PK₨142 per share. Announcement • Dec 18
The Searle Company Limited Appoints Syed Nadeem Ahmed as Chief Executive Officer The Searle Company Limited announced that Board of Directors of the company in their meeting held on December 16, 2020 has appointed Mr. Syed Nadeem Ahmed as Chief Executive Officer of the company. Is New 90 Day High Low • Nov 19
New 90-day low: PK₨234 The company is down 6.0% from its price of PK₨249 on 21 August 2020. The Pakistani market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is PK₨132 per share. Reported Earnings • Nov 03
First quarter 2021 earnings released: EPS PK₨2.99 The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: PK₨5.56b (up 12% from 1Q 2020). Net income: PK₨635.6m (up 16% from 1Q 2020). Profit margin: 11% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year. Analyst Estimate Surprise Post Earnings • Oct 11
Annual earnings released: Revenue and earnings beat expectations Annual revenue exceeded analyst estimates by 6.0% at PK₨20.5b. Earnings per share (EPS) also surpassed analyst estimates by 21% at PK₨11.77. Revenue is forecast to grow 26% over the next year, compared to a 66% growth forecast for the Pharmaceuticals industry in Pakistan. Reported Earnings • Oct 11
Full year earnings released - EPS PK₨11.77 Over the last 12 months the company has reported total profits of PK₨2.50b, up 12% from the prior year. Total revenue was PK₨20.5b over the last 12 months, up 13% from the prior year. Profit margins were 12%, which is in line with last year. Reported Earnings • Oct 01
Full year earnings released - EPS PK₨11.77 Over the last 12 months the company has reported total profits of PK₨2.50b, up 12% from the prior year. Total revenue was PK₨20.5b over the last 12 months, up 13% from the prior year. Profit margins were 12%, which is in line with last year.